Using glutaminase I isoforms to identify prostate cancer treatment responses
Glutaminase I isoforms as personalized biomarkers of prostate cancer
This study is looking at how different versions of a specific enzyme can help doctors understand how prostate cancer behaves and responds to hormone treatments, with the goal of finding better, personalized treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11003270 on NIH RePORTER |
What this research studies
This research investigates how different forms of the enzyme glutaminase I can serve as personalized biomarkers for prostate cancer. By analyzing the expression of these isoforms in patients, the study aims to understand how prostate cancer responds to hormonal therapies and why some patients develop resistance to treatment. The approach involves examining tumor samples to identify which isoform is present, potentially guiding more effective treatment strategies tailored to individual patients. This could lead to improved prognostic tools for predicting therapy outcomes in prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who are undergoing or considering hormonal therapy.
Not a fit: Patients with early-stage prostate cancer or those not receiving hormonal therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide personalized treatment options for prostate cancer patients, improving their chances of effective therapy.
How similar studies have performed: Previous research has shown promise in using biomarkers for personalized cancer treatment, suggesting that this approach could yield significant insights.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Huang, Jiaoti — Duke University
- Study coordinator: Huang, Jiaoti
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.